Live tape
Top 8, mentions 7d10,599TSLA2,252 mentions▲ +0.05GOOGL1,490 mentions▲ +0.04CRWV1,422 mentions▲ +0.03SPCX1,339 mentions▲ +0.07NVDA1,184 mentions▲ +0.07QQQ1,154 mentions▲ +0.05NBIS915 mentions▲ +0.06META843 mentions▲ +0.05

Equity · Healthcare

INVA

NASDAQ

Innoviva (INVA)

$21.49 +1.01% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Aug 19, 2026
Price · Chart
21 sessions
$22.0 $20.0 22 Jul 19 Aug

The line runs $21.43 on 22 July through $21.49 on 19 August, on a scale from $20.0 to $22.0. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 21 sessions, 22 Jul – 19 Aug 2026
Market cap $1.6B
P/E (TTM) 4.9
52-week range $16.69 – $24.24
Avg volume 126.6K

as of Aug 19, 2026

Innoviva (INVA) insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 20 Aug 2026

In the 90 days to 21 Oct 2026, no Innoviva insider bought or sold shares on the open market; all 3 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).

Open-market buys 0
Open-market sells 0
Non-trade filings 3

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
20 Aug 2026 Zhen Marianne Chief Accounting Officer Tax withheld 1,127 $24K
20 Aug 2026 Basso Stephen Chief Financial Officer Tax withheld 558 $12K
20 Aug 2026 Raifeld Pavel Chief Executive Officer Tax withheld 1,130 $24K

Innoviva (INVA) reported financials

SEC EDGAR XBRL SEC EDGAR

Innoviva reported revenue of $411.3M for the fiscal year ended 31 Dec 2025. Net income over the same period was $271.2M.

Figure Reported Period
Revenue $411.3M 31 Dec 2025 fiscal year
Net income to common shareholders $271.2M 31 Dec 2025 fiscal year
Diluted EPS $3.30 31 Dec 2025 fiscal year
Total assets $1.7B 30 Jun 2026 at period end
Total equity $1.2B 30 Jun 2026 at period end

Innoviva (INVA) earnings

SEC EDGAR

Innoviva last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$1.14; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$1.14 —
31 Mar 2026 Q1 2026 $2.22 —
31 Dec 2025 FY 2025 $3.30 —
30 Sep 2025 Q3 2025 $1.08 —
30 Jun 2025 Q2 2025 $0.77 —
31 Mar 2025 Q1 2025 −$0.74 —
31 Dec 2024 FY 2024 $0.36 —
30 Sep 2024 Q3 2024 $0.02 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Innoviva (INVA) institutional holders (13F)

SEC Form 13F SEC EDGAR

8 of the 45 institutional funds we track reported a Innoviva position for the quarter ended 30 Jun 2026 — a combined $232.8M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Renaissance Technologies Held (±25%) −0.5% shares 4,036,532 $91.7M
Millennium Management Held (±25%) +11.5% shares 2,541,109 $57.7M
Marshall Wace Held (±25%) −3.3% shares 1,454,319 $33.0M
Two Sigma Investments Trimmed −30.4% shares 1,032,807 $23.5M
AQR Capital Management Held (±25%) +10.8% shares 549,553 $12.5M
Balyasny Asset Management Held (±25%) −11.3% shares 285,610 $6.5M
Citadel Advisors Held (±25%) +5.5% shares 185,750 $4.2M
D. E. Shaw & Co. Trimmed −33.2% shares 166,255 $3.8M
Man Group Exited

Innoviva (INVA) fails-to-deliver

SEC CNS data SEC

On 16 Sep 2026, 1,000 shares of Innoviva failed to deliver (about $21K).

Settlement date Shares failed Notional % of shares out
16 Sep 2026 1,000 $21K 0.001%

Congressional trades in Innoviva (INVA)

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in Innoviva is a sale by George Whitesides (house, CA), dated 25 Mar 2025.

Date Member Type Amount
25 Mar 2025 filed 23 Apr 2025 George Whitesides house · Democrat–CA Sale $250K–$500K

Innoviva (INVA): frequently asked questions

From live data

Have Innoviva insiders bought or sold shares recently?

In the 90 days to 21 Oct 2026, no Innoviva insider bought or sold shares on the open market; all 3 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).

How many institutions hold Innoviva?

8 of the 45 institutional funds we track reported a Innoviva position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Innoviva had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Innoviva is dated 16 Sep 2026, when 1,000 shares failed to deliver.

When did Innoviva last report earnings?

Innoviva last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$1.14; no next date is announced in SEC filings yet.

What exchange is Innoviva listed on?

Innoviva trades on NASDAQ under the ticker INVA.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SEC EDGARValuation computed from SEC EDGAR filings